An Integrated Approach To Identify The Molecular Mechanisms Contributing To The Pathogenesis Of Insulin Resistance: Targeting The Liver And Skeletal Muscle
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
The inability of muscle and liver to utilise sugar from the blood is a major problem that contributes to the development of obesity and diabetes. How these problems occur is unknown. The goal of my research is to identify what causes the muscle and liver problem, and whether fixing these problems will reduce obesity and diabetes. Since the number of people with obesity and diabetes is predicted to double over the next decade, we need to understand the cause of these diseases.
Determining The Cost-effectiveness Of A Novel Australian Stroke Telemedicine Program: CAST Study
Funder
National Health and Medical Research Council
Funding Amount
$496,015.00
Summary
Urgent treatment of acute stroke in rural Australia is problematic. Telemedicine could improve delivery of acute stroke treatments in rural communities. Currently this is being investigated through the Victorian Stroke Telemedicine (VST) program by providing an acute telestroke service in 16 hospitals located in rural and regional Victoria. This project, known as CAST, forms an important sub-study for the VST program since it provides a full economic evaluation of the program.
ELders AT Ease Program (ELATE): A Cluster Randomised Controlled Trial Of A Sustainable And Scalable Mental Health Service For Australian Residential Aged Care Facilities
Funder
National Health and Medical Research Council
Funding Amount
$999,551.00
Summary
Elders living in residential facilities suffer significant levels of depression or anxiety. This study examines an innovative program to improve mental health of residents living in such facilities. The program involves counselling, staff training and family support. The study uses a cluster randomised controlled trial of facilities to evaluate the impact of ELATE: Elders at Ease Program” on residents’ psychological wellbeing, staff knowledge, family carer stress and, health care costs.
Centre For Research Excellence To Promote Safer Families: Tailoring Early Identification And Novel Interventions For Intimate Partner Violence
Funder
National Health and Medical Research Council
Funding Amount
$2,497,801.00
Summary
Partner violence damages the health of families, particularly children. We aim to make all families safer by generating new knowledge from evidence (reviews of studies, data from following families over time and trials of health and community programs) to assist health and family services to identify violence early and tailor responses to individual’s experiences and to specific communities. We will support early career researchers by mentoring and an international network.
A Randomised Trial Of A Clinical Prediction Tool For Targeting Depression Care (Target-D)
Funder
National Health and Medical Research Council
Funding Amount
$944,774.00
Summary
The Target-D Study uses a novel clinical prediction tool to test a new approach to depression care in general practice based upon sub-grouping patients into low, medium and high risk of ongoing depression. Participants will be randomly allocated to targeted treatments based upon their risk profile or to usual general practice care. We will measure whether the new approach results in greater improvements in depressive symptoms, quality of life and functioning and whether there are cost benefits.
Developing Social Media Based Approaches To Youth Suicide Prevention
Funder
National Health and Medical Research Council
Funding Amount
$319,831.00
Summary
This project aims to capitalise on the popularity and accessibility of social media by developing a suite of suicide prevention tools that can be delivered via these types of platform. Examples of interventions include mood tracking and safety-planning tools delivered as mobile phone apps, and personal stories (vox pops) delivered via platforms such as Facebook and/or YouTube. The project will engage young people in every stage of intervention planning, development and evaluation.
Preclinical Development Of A Therapeutic Anticancer Antibody To C-Met
Funder
National Health and Medical Research Council
Funding Amount
$435,530.00
Summary
Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.
Improving Quality Of Life In Late Stage Bipolar Disorder: RCT Of A Novel Psychological Treatment
Funder
National Health and Medical Research Council
Funding Amount
$1,083,620.00
Summary
Hundreds of thousands of Australians have bipolar disorder and receive minimal benefit from existing drug and psychological treatments. ORBIT 2.0 is a new low-intensity online treatment using mindfulness strategies to improve quality of life in this poorly served ‘late stage’ group. Pilot testing suggests ORBIT is effective. This project will refine the intervention and is expected to confirm its clinical and cost effectiveness prior to international roll-out.
Integrating Immunity And Genetics In Follicular Lymphoma To Establish A Prognostic Score Fit For The Modern Era
Funder
National Health and Medical Research Council
Funding Amount
$1,377,174.00
Summary
Follicular lymphoma (FL) is divided into early and advanced stages. Early stage FL is frequently cured, but there is no way to identify who will be cured and who won't. By contrast advanced stage FL is incurable. Our unique access to well-annotated clinical trial and population based cohorts allows us to perform a detailed biological comparison of early and advanced FL, to gain a deeper understanding of the impediments to eradicating the disease, and to predict outcome to conventional therapy.
Development Of Therapeutically Useful Human Artificial Chromosomes For Gene Delivery And Optimal Gene Expression
Funder
National Health and Medical Research Council
Funding Amount
$496,986.00
Summary
Gene therapy is an exciting new form of treatment for genetic disorders aimed at providing long-term correction of the problems at source - namely the affected gene. The biggest technical hurdle facing gene therapy is to be able to deliver the therapeutic genes efficiently and safely into patient cells. Many gene therapy protocols are currently being trialled clinically. These protocols, based mostly on the use of attenuated viruses to deliver the genes, carry potential risks to the patients in ....Gene therapy is an exciting new form of treatment for genetic disorders aimed at providing long-term correction of the problems at source - namely the affected gene. The biggest technical hurdle facing gene therapy is to be able to deliver the therapeutic genes efficiently and safely into patient cells. Many gene therapy protocols are currently being trialled clinically. These protocols, based mostly on the use of attenuated viruses to deliver the genes, carry potential risks to the patients in terms of infection, immune response, and germline modification. We have developed the first stage of a new technology for gene delivery that does not require the use of viruses. This technology is based on the generation of human artificial chromosomes, which are smaller versions of the naturally occurring chromosomes that carry all the genes inside our cells. Safety in these artificial chromosomes comes from the use of entirely human materials for their engineering. These artificial chromosomes also have other advantages over the viral approaches, including allowing large genes to be carried, and providing a permanent cure in a single treatment. We have already successfully constructed, published, and patented a number of first-generation human artificial chromosomes. The current project aims to complete the next proof-of-concept milestone towards the further development of this technology. Specifically, we propose to demonstrate the ability of the artificial chromosomes to carry genes and provide sustainable expression of these genes in cells and in animal models. Success in this study will allow the technology to proceed rapidly into commercialisation and clinical trial as a new improved tool for gene delivery and gene therapy.Read moreRead less